Clinical Trials Logo

DLBCL clinical trials

View clinical trials related to DLBCL.

Filter by:
  • Approved for marketing  
  • Page 1

NCT ID: NCT04300803 Approved for marketing - DLBCL Clinical Trials

Expanded Access Program for Tafasitamab (MOR00208) in R/R DLBCL

Start date: n/a
Phase:
Study type: Expanded Access

Expanded Access Program (EAP) to provide Tafasitamab (MOR208) to eligible patients with relapsed or refractory Diffuse Large B Cell Lymphoma. Access to MorphoSys´ EAP can be requested by contacting the respective CRO Clinigen (tafasitamab@clinigengroup.com).